Page last updated: 2024-10-19

thioctic acid and Schizophrenia

thioctic acid has been researched along with Schizophrenia in 20 studies

Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

ExcerptRelevanceReference
"Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population."5.48Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018)
" The present study aimed to investigate the effects of the typical antipsychotic chlorpromazine (CP) alone or combined with the natural antioxidant alpha-lipoic acid (ALA) on changes in the hippocampal average spectral power induced by ketamine (KET)."5.46Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017)
"5 improved most of the parameters evaluated in this study without causing motor impairment demonstrating, thus, that possibly when combined with ALA a lower dose of CLZ is required."5.42Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. ( de Lucena, DF; de Sousa, CN; Gama, CS; Lima, LL; Macêdo, D; Oliveira, Tde Q; Vasconcelos, GS; Vasconcelos, SM; Ximenes, NC, 2015)
"Schizophrenia is a chronic condition that impacts significantly not only on the individual and family, but the disorder also has wider consequences for society in terms of significant costs to the economy."2.50Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. ( Arroll, MA; Neil, J; Wilder, L, 2014)
"Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population."1.48Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018)
" The present study aimed to investigate the effects of the typical antipsychotic chlorpromazine (CP) alone or combined with the natural antioxidant alpha-lipoic acid (ALA) on changes in the hippocampal average spectral power induced by ketamine (KET)."1.46Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017)
"Schizophrenia is a chronic mental illness in which mitochondrial dysfunction has been suggested."1.43Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model. ( Deslauriers, J; Grignon, S; Monpays, C; Sarret, P, 2016)
"5 improved most of the parameters evaluated in this study without causing motor impairment demonstrating, thus, that possibly when combined with ALA a lower dose of CLZ is required."1.42Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. ( de Lucena, DF; de Sousa, CN; Gama, CS; Lima, LL; Macêdo, D; Oliveira, Tde Q; Vasconcelos, GS; Vasconcelos, SM; Ximenes, NC, 2015)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.00)29.6817
2010's16 (80.00)24.3611
2020's2 (10.00)2.80

Authors

AuthorsStudies
Mishra, A1
Reeta, KH1
Sarangi, SC1
Maiti, R1
Sood, M1
Dutta, A1
Karanth, SS1
Bhattacharya, M1
Liput, M1
Augustyniak, J1
Cheung, M1
Stachowiak, EK1
Stachowiak, MK1
Sanders, LLO1
de Souza Menezes, CE1
Chaves Filho, AJM1
de Almeida Viana, G1
Fechine, FV1
Rodrigues de Queiroz, MG1
Gonçalvez da Cruz Fonseca, S1
Mendes Vasconcelos, SM1
Amaral de Moraes, ME1
Gama, CS2
Seybolt, S1
de Moura Campos, E1
Macêdo, D4
Freitas de Lucena, D1
Sampaio, LRL2
Cysne Filho, FMS1
de Almeida, JC1
Diniz, DDS1
Patrocínio, CFV1
de Sousa, CNS1
Patrocínio, MCA2
Vasconcelos, SMM2
Ratliff, JC1
Palmese, LB1
Reutenauer, EL1
Tek, C1
Deslauriers, J2
Racine, W1
Sarret, P2
Grignon, S2
Emsley, R2
Chiliza, B2
Asmal, L2
du Plessis, S2
Phahladira, L2
van Niekerk, E2
van Rensburg, SJ2
Harvey, BH2
Vidović, B2
Milovanović, S2
Dorđević, B1
Kotur-Stevuljević, J2
Stefanović, A2
Ivanišević, J1
Miljković, M1
Spasić, S1
Stojanović, D1
Pantović, M2
Arroll, MA1
Wilder, L1
Neil, J1
Seybolt, SE3
Vasconcelos, GS1
Ximenes, NC1
de Sousa, CN1
Oliveira, Tde Q1
Lima, LL1
de Lucena, DF1
Vasconcelos, SM1
Monpays, C1
Kim, NW1
Song, YM1
Kim, E2
Cho, HS2
Cheon, KA1
Kim, SJ1
Park, JY1
Borges, LTN1
Barbosa, TM1
Matos, NCB1
Lima, RF1
Oliveira, MN1
Gularte, VN1
Vale, OCD1
Takić, M1
Debeljak-Martačić, J1
Đorđević, B1
ALTSCHULE, MD1
GONCZ, RM1
HOLLIDAY, PD1
Park, DW1
Choi, SH1
Kim, JJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial[NCT03788759]Phase 2/Phase 348 participants (Actual)Interventional2019-09-01Completed
An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia[NCT01355952]17 participants (Actual)Interventional2011-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for thioctic acid and Schizophrenia

ArticleYear
Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review.
    Nutrition journal, 2014, Sep-16, Volume: 13

    Topics: Acetylcysteine; Antipsychotic Agents; Ascorbic Acid; Databases, Factual; Diet, Gluten-Free; Dietary

2014

Trials

7 trials available for thioctic acid and Schizophrenia

ArticleYear
Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial.
    Psychopharmacology, 2022, Volume: 239, Issue:11

    Topics: Antioxidants; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Double-Blind Method; Drug The

2022
α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:6

    Topics: Adult; Antioxidants; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle A

2017
A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
    Schizophrenia research, 2014, Volume: 158, Issue:1-3

    Topics: Adult; Antioxidants; Antipsychotic Agents; Docosahexaenoic Acids; Double-Blind Method; Drug Therapy,

2014
Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia.
    Psychiatria Danubina, 2014, Volume: 26, Issue:3

    Topics: Adult; Advanced Oxidation Protein Products; Antioxidants; Antipsychotic Agents; Blood Glucose; Drug

2014
Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.
    International clinical psychopharmacology, 2016, Volume: 31, Issue:5

    Topics: Adult; Antioxidants; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; H

2016
Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia.
    Journal of medicinal food, 2017, Volume: 20, Issue:1

    Topics: Adipokines; Adiponectin; Adult; Blood Glucose; Dietary Supplements; Female; Humans; Insulin; Leptin;

2017
A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Adult; Antioxidants; Antipsychotic Agents; Appetite; Blood Glucose; Body Mass Index; Brief Psychiatr

2008

Other Studies

12 other studies available for thioctic acid and Schizophrenia

ArticleYear
A proof of concept 'phase zero' study of neurodevelopment using brain organoid models with Vis/near-infrared spectroscopy and electrophysiology.
    Scientific reports, 2020, 12-02, Volume: 10, Issue:1

    Topics: Acetylcarnitine; Brain; Case-Control Studies; Cell Line; Choline; Electron Transport Complex IV; Ele

2020
Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences.
    Neuroscience, 2018, 03-01, Volume: 373

    Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Drug Therapy, C

2018
An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes.
    Clinical schizophrenia & related psychoses, 2015, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Aged; Antioxidants; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Obes

2015
Preventive effect of α-lipoic acid on prepulse inhibition deficits in a juvenile two-hit model of schizophrenia.
    Neuroscience, 2014, Jul-11, Volume: 272

    Topics: Aging; Animals; Disease Models, Animal; Female; Male; Mice, Inbred C57BL; Prefrontal Cortex; Pregnan

2014
Less is more.
    Schizophrenia research, 2014, Volume: 160, Issue:1-3

    Topics: Antioxidants; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Male; Psychotropic Drugs

2014
Re: Less is more.
    Schizophrenia research, 2014, Volume: 160, Issue:1-3

    Topics: Antioxidants; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Male; Psychotropic Drugs

2014
In response to re: less is more.
    Schizophrenia research, 2015, Volume: 161, Issue:2-3

    Topics: Antioxidants; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Male; Psychotropic Drugs

2015
Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
    Schizophrenia research, 2015, Volume: 165, Issue:2-3

    Topics: Analysis of Variance; Animals; Antioxidants; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic

2015
Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model.
    Journal of molecular neuroscience : MN, 2016, Volume: 59, Issue:4

    Topics: Animals; Cell Respiration; Corpus Striatum; Electron Transport Complex I; Electron Transport Complex

2016
Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats.
    Journal of psychiatric research, 2017, Volume: 86

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease Models, Animal;

2017
Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?
    Medical hypotheses, 2010, Volume: 75, Issue:6

    Topics: Antioxidants; Dopamine; Glutathione; Glutathione Disulfide; Humans; Mitochondria; Mitochondrial Memb

2010
Carbohydrate metabolism in brain disease. XI. Effects of thioctic (alpha-lipoic) acid in chronic schizophrenia.
    A.M.A. archives of internal medicine, 1959, Volume: 103, Issue:5

    Topics: Brain Diseases; Carbohydrate Metabolism; Carbohydrates; Humans; Schizophrenia; Thioctic Acid; Vitami

1959